Group 1 - Brown Advisory Mid-Cap Growth Strategy underperformed the Russell Midcap® Growth Index in Q4 2025 due to stock selection, particularly missing out on Palantir Technologies Inc (PLTR) [1] - The Strategy aims for solid risk-adjusted returns by investing in high-quality compounders with market capitalizations between $2 billion and $50 billion at the time of purchase [1] - Medline Inc. (NASDAQ:MDLN) was highlighted as a key stock, with a market capitalization of $34.479 billion, closing at $42.48 per share on March 23, 2026 [2] Group 2 - Medline Inc. was purchased during its IPO, and the company is noted for its vertically integrated manufacturing and distribution platform, which provides a competitive advantage [3] - Despite acknowledging Medline's potential, the firm believes certain AI stocks present greater upside potential and less downside risk [5] - At the end of Q4 2025, 58 hedge fund portfolios held Medline Inc., but it was not among the 40 most popular stocks among hedge funds heading into 2026 [5]

Core Viewpoint - Kewaunee Scientific Corporation plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after trading hours [1] Company Overview - Kewaunee Scientific Corporation, founded in 1906, is a global leader in designing, manufacturing, and installing laboratory, healthcare, and technical furniture products [1] - The company offers a range of products including steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks [1] - Corporate headquarters are located in Statesville, North Carolina, with sales offices in the United States, India, Saudi Arabia, and Singapore [1] - Kewaunee operates three manufacturing facilities in Statesville and one in Bangalore, India, serving both domestic and international markets [1] Recent Acquisition - Kewaunee Scientific's newly acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products [1] - Nu Aire was founded in 1971 and has its headquarters and manufacturing facilities in Plymouth, Minnesota, with additional capabilities in Long Lake, Minnesota, and a warehouse partnership in the Netherlands [1]

Core Points - Nanalysis Scientific Corp. announces the resignation of Chief Financial Officer Randall McRae effective December 5, 2025, with Heather Kury appointed as Interim CFO during the search for a permanent successor [1][3] - Heather Kury brings over twenty years of experience in corporate strategy and operational excellence, having held senior roles in the oil and gas and information technology sectors [2] - Nanalysis develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used in various industries, and operates a services division with a $160 million long-term contract with the Canadian Air Transport Security Authority [4]

Market Overview - Pre-market futures are showing a downward bias, with the Dow down -9 points, S&P 500 up +3, Nasdaq down -38, and Russell 2000 down -9 points [1] - The Dow recently reached a record closing high, but Q3 earnings reports have not been as positive as expected [1] Federal Reserve Insights - Fed Governor Michael Barr is scheduled to make appearances ahead of the upcoming monetary policy decision, with nearly 100% of analysts anticipating a 25 basis-point rate cut [2] Q3 Earnings Reports - **AT&T (T)**: Reported Q3 earnings of 54 cents per share, missing estimates by a penny, with revenues of $30.71 billion, down -0.81% from estimates; shares down -1.6% [3] - **Thermo Fisher (TMO)**: Reported earnings of $5.79 per share, beating estimates of $5.50, with revenues of $11.12 billion, exceeding expectations by +2%; shares up +2% [4] - **GE Vernova (GEV)**: Reported earnings of $1.64 per share, missing estimates of $1.78 by -7.87%, but revenues of $9.97 billion were +8.62% higher than anticipated; shares up +3.8% [5] - **Teck Resources (TECK)**: Reported earnings of 55 cents per share, surpassing estimates of 39 cents by +41%, with revenues of $2.46 billion, exceeding consensus by +14.3% [6] Upcoming Earnings Expectations - **Tesla (TSLA)**: Expected to report negative earnings per share down -26.4% year over year, but +5% on revenues; shares are flat ahead of the report [7] - **IBM (IBM)**: Anticipated to report earnings +6% higher and revenues +7.57% higher, with shares up +28% year to date [8] - **Southwest Airlines (LUV)**: Facing a tough year-over-year comparison with expected earnings growth down -93% and revenues up +1.44% [8]

Core Insights - STERIS plc is a global leader in infection prevention and sterilization solutions with a market cap of $23.9 billion, providing a diverse range of products and services to healthcare sectors [1] Financial Performance - Analysts expect STERIS to report Q2 earnings of $2.38 per share, reflecting an 11.2% increase from $2.14 per share in the same quarter last year, with the company having consistently met or exceeded Wall Street's estimates in the past four quarters [2] - For fiscal 2026, earnings are projected to be $10.07 per share, a 9.2% increase from $9.22 in fiscal 2025 [3] Stock Performance - STERIS stock has increased by 7.9% over the past 52 weeks, underperforming the S&P 500 Index's 15.1% gain but outperforming the Health Care Select Sector SPDR Fund's 4.1% decline [4] Market Concerns - On September 25, STERIS shares fell by 3% following a national security investigation into medical equipment imports, which could result in new tariffs affecting various medical products, leading to concerns about supply chains and production costs across the healthcare manufacturing sector [5] Analyst Ratings - The consensus opinion on STERIS stock is a "Moderate Buy," with six out of nine analysts recommending a "Strong Buy" and three suggesting a "Hold," indicating a potential upside of 15% based on an average price target of $278.29 [6]